AbstractObjectiveTo synthesise the evidence for estimating the direct and indirect patient costs of drug‐sensitive and drug‐resistant tuberculosis care in India.MethodPubMed, Embase, Web of Science, IndMED and Google Scholar were searched for studies conducted in India between 2000 and 2018 and published in English. The search terms were “tuberculosis” AND “costs” (cost Analysis, economics, cost of illness, health care costs, health expenditures, direct service costs, catastrophic cost) AND “India”. The cost of TB care was from the patient’s perspective. Data regarding costs were extracted, indexed to the year 2018 using cumulative inflation rate and converted to US dollars at the exchange rate of 2018.ResultsThirteen studies were included in this review. The mean (unweighted) total cost incurred by patients being treated for drug‐sensitive TB in a public health facility was $ 235.00 (SD‐ 222.10), and the median of means was $ 170.60 (range – 43.70–718.40). The mean direct cost was 45.5% of the total cost. Only one study, which was conducted in a private facility, reported the mean total cost for drug‐resistant TB as $ 7778.04. Catastrophic cost (total cost ≥ 20% of the total annual household income) was experienced by 7% to 32.4% of drug‐sensitive TB patients and by 68% of drug‐resistant TB patients.ConclusionDespite free diagnostic and treatment services provided under the Revised National Tuberculosis Control Programme, the patient cost of tuberculosis care is high. Relevant studies vary widely in methodology and cost reporting.